

Arkansas Department of Human Services - Division of Medical Services

HB 1332 - GLP-1 - Fiscal Impact Analysis

Graded Fiscal Impact

	Description	2% Utilization Increase	5% Utilization Increase
Pre Rebate	Total Computable Cost Pre Rebate	\$25,225,518	\$63,063,796
	Federal Share Pre Rebate	\$17,584,078	\$43,960,196
	State Share Pre Rebate	<u>\$7,641,440</u>	<u>\$19,103,600</u>

We are currently spending \$11.5 Million per year on GLP-1s for diabetes and other non obesity FDA Approved indications. We estimate a graded range total computable impact of \$25 - \$63 Million, or \$7.6 - \$19.1 Million State Share. This is the estimate of immediate cost, excluding any drug rebate estimates which are received in later quarters.

Prepared by Arkansas Department of Human Services